Nevro Corp

$87.78

+1.49 (+1.73%) Today
1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

2 Years 2Y

5 Years 5Y

Max Max

More Nevro Corp News

Nevro Announces Two Health Economic Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2021 Meeting Nov 30, 2021

REDWOOD CITY, Calif., Nov. 30, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced two poster presentations at the International Society for

Nevro Corp. (NYSE: NVRO): Can A Stock Thats Down -46.51% YTD Still Be Considered In Loss Territory? Nov 25, 2021

During the last session, Nevro Corp. (NYSE:NVRO)s traded shares were 0.82 million, with the beta value of the company hitting 1.00. At the end of the trading day, the stocks price was $92.59, reflecting an intraday gain of 5.25% or $4.62. The 52-week high for the NVRO share is $188.14, that puts it down -103.2 Nevro Corp. (NYSE: NVRO): Can A Stock Thats Down -46.51% YTD Still Be Considered In Loss Territory? Read More »

Weekly Research Analysts Ratings Updates for Nevro (NVRO) Nov 25, 2021

Several brokerages have updated their recommendations and price targets on shares of Nevro (NYSE: NVRO) in the last few weeks: 11/19/2021 Nevro had its buy rating reaffirmed by analysts at SVB Leerink LLC. They now have a $128.00 price target on the stock. 11/9/2021 Nevro had its price target lowered by analysts at []

Nevro (NYSE:NVRO) Stock Rating Reaffirmed by SVB Leerink Nov 21, 2021

SVB Leerink reiterated their buy rating on shares of Nevro (NYSE:NVRO) in a report published on Friday morning, TipRanks reports. SVB Leerink currently has a $128.00 target price on the medical equipment providers stock. NVRO has been the subject of a number of other reports. Truist Financial downgraded Nevro to a hold rating and set []

$96.54 Million in Sales Expected for Nevro Corp. (NYSE:NVRO) This Quarter Nov 20, 2021

Analysts forecast that Nevro Corp. (NYSE:NVRO) will post $96.54 million in sales for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Nevros earnings. The lowest sales estimate is $95.88 million and the highest is $97.47 million. Nevro reported sales of $109.73 million during the same quarter last year, which would []

Nevro Corp.: When The Timing Is Right, Sit Tight Nov 20, 2021

Nevro Corp. (NYSE:NVRO) price on Friday, November 19, fall -1.64% below its previous days close as a downside momentum from buyers pushed the stocks value to $86.83. A look at the stocks price movement, the close in the last trading session was $88.28, moving within a range at $86.04 and $90.99. The beta value (5-Year Nevro Corp.: When The Timing Is Right, Sit Tight Read More »

Global Pain Management Devices Market Report 2021 Featuring NeuroMetrix, Medtronic, Boston Scientific, Zynex Medical, BioElectronics, SPR Therapeutics, BD & Co Abbott, & Nevro Nov 18, 2021

DUBLIN, Nov. 18, 2021 /PRNewswire/ -- The "Pain Management Devices Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com''s offering. The global pain management devices market is expected to grow at a compound annual growth rate of 11.04% over the forecast

AQR Capital Management LLC Cuts Stock Position in Nevro Corp. (NYSE:NVRO) Nov 16, 2021

AQR Capital Management LLC lessened its stake in shares of Nevro Corp. (NYSE:NVRO) by 17.9% in the 2nd quarter, Holdings Channel.com reports. The firm owned 7,653 shares of the medical equipment providers stock after selling 1,666 shares during the quarter. AQR Capital Management LLCs holdings in Nevro were worth $1,269,000 as of its most recent []

Zacks: Analysts Expect Nevro Corp. (NYSE:NVRO) to Announce -$0.85 EPS Nov 16, 2021

Brokerages forecast that Nevro Corp. (NYSE:NVRO) will report earnings of ($0.85) per share for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Nevros earnings, with estimates ranging from ($0.93) to ($0.74). Nevro reported earnings of ($0.21) per share during the same quarter last year, which would indicate a negative year-over-year []

Nevro Corp. (NYSE:NVRO) Shares Sold by MetLife Investment Management LLC Nov 13, 2021

MetLife Investment Management LLC lowered its position in shares of Nevro Corp. (NYSE:NVRO) by 5.2% in the second quarter, Holdings Channel reports. The institutional investor owned 12,102 shares of the medical equipment providers stock after selling 668 shares during the quarter. MetLife Investment Management LLCs holdings in Nevro were worth $2,006,000 at the end of []

About

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

CEO

D.Keith Grossman

Employees

804

Headquarters

1800 Bridge Pkwy , Redwood City, California 94065-1164 US

Founded

2006